StimLabs Announces Exclusive Distribution Rights for Geistlich’s Leading Wound Care Portfolio | PR Newswire [Video]

 New Partnership Expands StimLabs Product Offering to Include Medicare Covered Xenograft, Derma-Gide (Q4203)

, /PRNewswire/ — StimLabs, a leading regenerative medicine company, announced that it has entered into an exclusive national distribution agreement with Geistlich to commercialize an innovative wound care product line, beginning with the advanced wound matrix, Derma-Gide^®. This strategic partnership broadens the StimLabs product portfolio to include xenografts and continues the company’s history of bringing unique regenerative solutions to the market.

“Our philosophy has been to drive progress in regenerative medicine and to ensure patients receive the most advanced and effective treatments available, while also meeting the varying needs of healthcare providers, sites of care, and payors,” said John Daniel, Founder and CEO of StimLabs. “Geistlich is a trusted leader in regenerative technologies, known for quality and innovation, and we are excited to bring their wound care products to the U.S. market. While this partnership supports diversification …